Category
Blog
-
2023
-
InnoCare Announces First Subject Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in China
-
Despite FDA doubts, advisors back first-line Polivy use
-
FDA Approves Pfizer’s Zavzpret in Acute Treatment of Migraine
-
Solanezumab Fails to Halt Amyloid and Cognitive Decline in Preclinical Alzheimer’s
-
US FDA approves Acadia Pharmaceuticals’ Rett syndrome therapy
-
Satellos Bioscience Announces Further Preclinical Progress with SAT-3153 as a Potential Treatment for Duchenne Muscular Dystrophy
-
FDA Offers Advice on NDAs for Postoperative Local Anesthetics
-
Paxlovid Gets Advisory Panel Support for Full FDA Approval
-
Mayo Clinic cancer expert highlights advancements in treating multiple myeloma
-
Xtandi Shows Promise in Prostate Cancer Trial